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Undoubtedly one of the major problems
that continues to bedevil the recognition and
classification of lymphomas is the ability of
pathologists to reliably and reproducibly
identify the component cells. This, in turn,
relates to the fixation and processing artefacts
of the relatively crude methods used in diag-
nostic histopathology. The -wider use of
cytology, plastic-embedded sections and
immunoenzyme labelling methods could do
much to overcome these problems. My major
criticism ofthis book is that it is based almost
entirely on paraffin-processed material and
the author is unable to illustrate the fine cyto-
logical detail necessary for the recognition
and separation ofthe different tumours ofthe
lymphoreticular system. Many of the illustra-
tions sho-w little more than a series of black
blobs of varying diameters and occasionally
of differing shapes, and are so unhelpful that
they might well have been omitted. This book
is intended for "clinical pathologists, ad-
vanced students, as -well as for oncologists,
histologists and researchers concerned -with
the study of malignant and non-malignant,
lymph cells". I very much regret that I cannot,
recommend it, to any of these groups.
D. H. WRIGHT
The Year in Hematology 1978. Eds. R.
SILBER, J. LOBUE, A. S. GORDON (1979).
New York: Plenum Medical Book Com-
pany. 517 pp. £18.58.
A vast amount of information concerning
clinical and experimental haematology has
accumulated in the last few years. This book
is part of a series which aims to reviewr recent
developments in a variety of fields. The sub-
jects discussed in the present volume range
from experimental topics ofgeneral biological
interest to others ofobvious interest to clinical
haematologists.
Myelo- and lympho-proliferative disorders
are analysed extensively from several angles,
with 6 chapters devoted to them. Four chap-
ters deal with experimental or laboratory
studies. The first reviews the effect of anti-
cancer drugs on the haemopoietic progenitor
cells wsNhich can be studied by in vivo or in
vitro colony assays, and discusses the possi-
bility that analysing the cytotoxicity of
chemotherapeutic agents on the basis of their
effect on the different types of the progenitor
cells studied, might provide a, more rational
approaclh to therapy. Another chapter de-
scribes the in vitro growith patterns of marrow
in acute and chronic granulocytic leukaemia
during various stages of the disease, and
analyses their relevance for the understanding
ofthe pathophysiology ofleukaemia. Data on
cell markers, including viral and foetal anti-
gens are analysed, and their possible relevance
if immunotherapeutic attack is considered,
are discussed critically. A comprehensive
review of the association of chromosome
abnormalities wNith acute leukaemias, chronic
myeloid leukaemias and other myelopro-
liferative disease, as wNell as pre-leukaemias
and lymphoproliferative diseases, gives a
detailed account ofthe information available.
Of considerable interest to clinicians will be
the chapters on treatment of Hodgkin's and
non-Hodgkin's lymphoma, wxvith a careful
analysis of the parameters that may decide
the type oftreatment.
Other chapters describe subjects w%hich will
be of interest to specialists, like those dealing
writh alterations on red-cell-membrane lipids,
factors w\hich regulate the egress of cells from
the marrow, mechanisms ofaction ofheparin,
observations on marrow megakaryocytes,
mechanisms of chloramphenicol and thi-
amphenicol toxicity, and haemoglobin
switch.
Finally, 2 conceptual chapters deal w%vith
the putative role ofproposed regulators ofthe
lympholhaemopoietic system: chalones, and
thymosin and other thymic factors.
The 14 chapters have been written by
authors who wNork actively in their respective
subjects and wrho succeed in providing com-
prehensive and authoritative reviews.
N. TESTA
The Handbook of Cancer Immunology.
Volume 5-Immunotherapy. Ed. HAR-
ROLD WATERS. New York: Garland STPM
Press. 478 pp.
This is the fifth in a series ofbooks designed
to reviewv the current status of tumour
immunology, and at first sight is rather a
"mixed bag" of some 17 chapters covering
experimental and clinical immunotherapy.
The main emphasis, however, is the immuno-
logical background of the disease and the
immunological effects of immunotherapeutic
agents and possible therapeutic techniques,
indicating their future potential, rather than